Financings in Brief: Sunrise Technologies
This article was originally published in The Gray Sheet
Executive Summary
Sunrise Technologies: Closes $5.9 mil. private placement of convertible notes and warrants. Funds will be used to complete the final clinical development phase of the LTK laser thermal keratoplasty corneal shaping system for treatment of hyperopia, and for continued trials for treatment of presbyopia. The financing is anticipated to provide sufficient funding "well into 1999," and filing by that time of a premarket approval application for hyperopia with FDA, the firm says. The offering includes 12% "payment-in-kind" convertible notes, maturing in January 2001. Investors receive one warrant for every $5 worth of notes. The warrants expire in five years and have an exercise price of $3 per share, which is also the conversion price on the notes...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.